FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Life Sciences Enterprise Capital Monitor – Europe 04/2022”.
The Monitor is a month-to-month printed overview of enterprise capital tendencies within the European Life Sciences sector.
As of the top of April 2022 we establish the next present VC tendencies in Europe:
- In 2022, general Life Sciences funding has reached EUR 3,421m up to now
- Prime 5 Offers exceed EUR 70m every, largest transaction amounted to EUR 500m in Doctolib (France)
- Two of the Prime 5 Offers passed off in Germany, Affected person21 (EUR 125m) and Ada Well being (EUR 106m)
- Bpifrance dominates the Prime 5 Traders (by deal quantity), adopted by Eurazeo (France) and Basic Atlantic (United States)
- The Biotech sector acquired 43% of the whole funding quantity
- Oncology dominates as the highest indication of the Biotechnology sector
To entry the total report, please click on right here.
By Dr. Mathias Schott, Sebastian Sommer and Johannes Hyperlink